Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for isotretinoin (oral formulations), the scientific conclusions are as follows:

Based on the review of large number of reported cases of vulvovaginal dryness and the biological plausibility in terms of similarity to well-established side-effects of isotretinoin, the PRAC considers that the there is sufficient evidence to justify inclusion of vulvovaginal dryness in section 4.8 of the SmPC and vaginal dryness in section 4 of the PL.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for isotretinoin (oral formulations) the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing isotretinoin (oral formulations) is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing isotretinoin (oral formulations) are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

The following adverse reaction should be added under the SOC “Reproductive system and breast disorders” with a frequency “unknown”:

Vulvovaginal dryness

Package Leaflet

- Section 4

Frequency not known (frequency cannot be estimated from the available data)

Vaginal dryness

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	December 2019 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	26/01/2020
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	26/03/2020